“…Despite increased serum exosomal miR‐210 expression was previously reported in glioma and renal cancer patients 13,22 raising doubts on its specificity for OSCC diagnosis, our and previous findings 12 demonstrate that miR‐210 act as an oncomiR in OSCC and its expression is not affected by age, gender, or relevant pathological variables such as TNM classification, further reinforcing the concept that EV‐miR‐210 secretion is indeed strictly related to the presence of the OSCC per se . From a clinical point of view, the early detection of OSCC offers several advantages: firstly, it allows to perform a conservative organ function surgery improving the quality of life of the patient after cancer removal 23 ; secondly, the early diagnosis could identify these tumors before they spread in the lymph node or invade surrounding tissue 24 . Finally, it has been shown that the removal of OSCC in an early stage prolongs the survival rate of these patients 25…”